Breaking News

Emergent BioSolutions Awarded $704M BARDA Contract for Ebola Treatment

Emergent will complete activities to advance the development of Ebanga treatment through post-licensure commitments.

Emergent BioSolutions Inc. was awarded a 10-year contract by the Biomedical Advanced Research and Development Authority (BARDA), within the U.S. Department of Health and Human Services (HHS), valued at up to a maximum of $704 million, for advanced development, manufacturing scale-up, and procurement of Ebanga (ansuvimab-zykl), a licensed treatment for Ebola virus disease (EVD). The contract consists of a base period of performance with two option periods for advanced development valued at app...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters